文献速递毛发、甲与色素性疾病

环孢素治疗中重度斑秃的双盲随机安慰剂对照试验

Cyclosporine for moderate-to-severe alopecia areata: A double-blind, randomized, placebo-controlled clinical trial of efficacy and safety.
PubMed 文献 · J Am Acad Dermatol · 2019-04-30

本研究为双盲随机安慰剂对照试验,纳入32例18-65岁中重度斑秃患者,1:1随机接受环孢素4 mg/kg/d或安慰剂治疗3个月。结论认为环孢素与安慰剂差异接近但未达统计学显著。

要点

  • 样本量小且单中心,结果解释和推广受限。

核心结论

  • 环孢素与安慰剂在3个月时的疗效差异接近但未达到统计学显著。

研究设计与样本

  • 双盲、随机、安慰剂对照临床试验,共分析32例18-65岁中重度斑秃患者,环孢素组和安慰剂组各16例。

关键数值与推荐

  • 环孢素剂量为4 mg/kg/d,疗程3个月。
  • 疗效评估采用Severity of Alopecia Tool评分及睫毛和眉毛评估量表。

临床怎么用

  • 环孢素4 mg/kg/d治疗3个月对中重度斑秃的眉毛改善可能有益,但整体疗效未达统计学显著,需结合个体情况谨慎使用。

局限性

  • 样本量小。
  • 单中心试验可能限制结果的解释和推广。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite widespread use of steroid-sparing agents, particularly cyclosporine, for treatment of alopecia areata (AA), there are no clinical trials investigating the efficacy of these agents. OBJECTIVE: To evaluate the efficacy of cyclosporine compared with placebo at 3 months in patients aged 18 to 65 years with moderate-to-severe AA. METHODS: A double-blind, randomized, placebo-controlled trial was conducted. Adults aged 18 to 65 years of age with moderate-to-severe AA were randomized in a 1:1 ratio to receive 3 months of cyclosporine (4 mg/kg/d) or matching placebo. Blinded assessments included physical examination, blood biochemistry, photography, quality of life measurements, and efficacy evaluation using Severity of Alopecia Tool score and eyelash and eyebrow assessment scales. RESULTS: The results obtained for 32 participants (16 who received cyclosporine and 16 who received placebo) were analyzed. Compared with the placebo group, the cyclosporine group had a greater proportion of participants achieving at least a 50% reduction in Severity of Alopecia Tool score (31.3% vs 6.3% [P = .07]) and greater proportion of participants achieving a 1-grade improvement in eyelash (18.8% vs 0% [P = .07]) and eyebrow (31.3% vs 0% [P = .02]) scale score. LIMITATIONS: Small sample size and single-institution trial may limit interpretation and generalizability of these results. CONCLUSION: Response approached but did not reach a statistically significant difference between cyclosporine and placebo.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Lai VWY, Chen G, Gin D, et al. Cyclosporine for moderate-to-severe alopecia areata: A double-blind, randomized, placebo-controlled clinical trial of efficacy and safety. J Am Acad Dermatol. 2019. PMID: 31048013. doi:10.1016/j.jaad.2019.04.053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。